Alpelisib vs. Alpelisib: two names for the same anticancer drug

When you mention Alpelisib, you are actually referring to an innovative drug calledAlpelisib. These are two names for the same anti-cancer drug, one is its Chinese name, and the other is its original English name. Alpelisib (Alpelisib), also widely recognized under the trade name Piqray, occupies a unique position in the anti-cancer field. This drug is the result of outstanding research by Novartis Pharmaceuticals. It targets phosphoinositide-3-kinase (PI3K) and is administered orally into the patient's body. Its precise molecular formula is C19H22F3N5O2S, and it has a relative molecular mass of 441.47g/mol, which fully demonstrates its scientific precision.

PI3K plays a crucial role in cell signaling. When this mechanism is disrupted or overactive, tumor cells may gain the opportunity to grow and spread disorderly. Fortunately, Alpelisib/Apelisib can interrupt this vicious cycle by specifically inhibiting the activity of PI3K, thereby achieving the purpose of effective treatment of malignant tumors.

In the United States, the drug has been approved by the Food and Drug Administration (FDA) and has become a recommended treatment in NCCN guidelines for certain types of breast cancer. This drug provides a new, targeted treatment option for patients with advanced or metastatic breast cancer who are estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and carry PIK3CA gene mutations. It has even become the first-choice second-line drug in this segment of the disease.

However, unfortunately, Apelvis is not yet available in the Chinese market. At the same time, because it belongs to the category of new drugs, its long-term efficacy and possible side effects still need to be confirmed by further clinical research and monitoring.